WRS
Well-known member
- Joined
- Mar 24, 2011
- Messages
- 16,985
- Reaction score
- 6,878
That's fair. And that's the argument they are making.
So call it closer to 90% than 62% within that window.
There are other benefits to the AZN version of the vaccine, as well.
Seems like storage and cost are huge for the AstraZeneca candidate, especially as it relates to reaching developing countries and rural geographies.